Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Benoît Rive

Datos Biográficos

ID7592283
NOMBREBenoît Rive
NOMBRESBenoît
APELLIDORive
FIRMARIVE B
AFILIACIONESJanssen (France)
VERIFICADONo
TOTAL DE OBRAS2
TOTAL DE CITAS0
TOTAL COMO AUTOR2
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2023
AÑO MÁS RECIENTE DE PUBLICACIÓN2024
ÍNDICE H0
  • Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission

    Open Access•Albino J Oliveira-Maia, Benoît Rive et al.•ARTICLE•Frontiers in Psychiatry•2024

    For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery

  • Iceberg study

    Open Access•Albino J Oliveira-Maia, Joachim Morrens et al.•ARTICLE•Frontiers in Psychiatry•2023

    ICEBERG supports that, at 6 months, esketamine NS has a substantial and significant benefit over RWT for patients with TRD. While results may be affected by unobserved confounding factors, threshold analyses suggested these were unlikely to impact the study conclusions.To view an animated summary of this publication, please click on the Supplementary video

Sin obras prominentes en esta página.

  • Iceberg study

    Open Access•Albino J Oliveira-Maia, Joachim Morrens et al.•ARTICLE•Frontiers in Psychiatry•2023

    ICEBERG supports that, at 6 months, esketamine NS has a substantial and significant benefit over RWT for patients with TRD. While results may be affected by unobserved confounding factors, threshold analyses suggested these were unlikely to impact the study conclusions.To view an animated summary of this publication, please click on the Supplementary video

  • Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission

    Open Access•Albino J Oliveira-Maia, Benoît Rive et al.•ARTICLE•Frontiers in Psychiatry•2024

    For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery

Anesthesia (2 obras) · Medicine (2 obras) · Nasal administration (2 obras) · Nasal spray (2 obras) · Pharmacology (2 obras) · Treatment of Major Depression (2 obras) · Confidence interval (1 obras) · Depression (economics (1 obras) · Geology (1 obras) · Ginkgo biloba and Cashew Applications (1 obras)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae